5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in Man - A PET study with [11C]raclopride

Neuropsychopharmacology

Volumn 20, Issue 5, 1999, Pages 424-433

  Vollenweider, Franz X ^a,b   Vontobel, Peter ^b   Hell, Daniel ^a   Leenders, Klaus L ^b,c  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

5 HT(1A) receptor; 5 HT(2A) receptor; 11C raclopride; D2 receptor; Dopamine; Human; Indoleamine hallucinogen; Model psychosis; Positron Emission Tomography (PET); Psilocybin; Psychopathology; Schizophrenia; Serotonin; Striatum

Indexed keywords

PSILOCYBINE; PSYCHEDELIC AGENT; RACLOPRIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; HUMAN; HUMAN CELL; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOSIS; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; DOPAMINE; DOPAMINE ANTAGONISTS; HALLUCINOGENS; HUMANS; MALE; PSILOCYBINE; PSYCHOMETRICS; PSYCHOSES, SUBSTANCE-INDUCED; RACLOPRIDE; SALICYLAMIDES; SEROTONIN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033136980     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00108-0     Document Type: Article

References (79)

1. Aghajanian G.K. LSD and phenethylamine hallucinogens. common sites of neuronal action Pletscher A., Ladewig D. 50 Years of LSD. Current Status and Perspectives of Hallucinogens. 1994;27-41 The Parthenon Publishing Group, New York.
2. Andreasen N.C., Rezai K., Alliger R., Swayze V.W., Flaum M., Kirchner P., Cohen G., O'Leary D.S. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch Gen Psychiatry. 49:1992;943-958.
3. Arora R.C., Meltzer H.Y. Serotonin 2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm. 85:1991;19-29.
4. Benloucif S., Keegan M.J., Galloway M.P. Serotonin-facilitated dopamine release in vivo. Pharmacological characterization J Pharmacol Exp Ther. 265:1993;373-377.
5. Benloucif S., Galloway M.P. Facilitation of dopamine release in vivo by serotonin agonists. studies with microdialysis Eur J Pharmacol. 200:1991;1-8.
6. Blandina P., Goldfarb J., Green J.P. Activation of a 5-HT3 receptor releases dopamine from rat striatal slice. Eur J Pharmacol. 155:1988;349-350.
7. Bonhomme N., De Deurwaerdere P., Le Moal M., Spampinato U. Evidence for 5-HT4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin. A microdialysis study in the halothane-anesthetized rat Neuropharmacology. 34:1995;269-279.
8. Boulenguez P., Rawlins J.N.P., Chauveau J., Joseph M.H., Mitchell S.N., Gray J.A. Modulation of dopamine release in the nuccleus accumbens by 5-HT1B agonists-involvement of the hippocampo-accumbens pathway. Neuropharmacology. 35:1996;1521-1529.
9. Bowers M.B., Freedman D.X. "Psychedelic" experiences in acute psychoses. Arch Gen Psychiatry. 15:1966;240-248.
10. Breier A., Adler C.M., Weisenfeld N., Su T.P., Elman I., Picken L., Malhotra A.K., Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects - application of a novel PET approach. Synapse. 29:1998;142-147.
11. Buchsbaum M.S., Haier R.J., Potkin S.G., Nuechterlein K., Bracha H.S., Katz M., Lohr J., Lottenberg S., Jerabek P.A., Trenary M., Tafalla R., Reynolds C., Bunney W.E. Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry. 49:1992;935-942.
12. Buckholtz N.S., Zhou D.F., Freedman D.X., Potter W.Z. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain. Neuropsychopharmacology. 3:1990;137-148.
13. Catafau A.M., Parellada E., Lomena F.J., Bernardo M., Pavia J., Ros D., Setoain J., Gonzalez-Monclus E. Prefrontal and temporal blood flow in schizophrenia. resting and activation technetium-99m-hmpao spect patterns in young neuroleptic-naive patients with acute disease J Nucl Med. 35:1994;935-941.
14. Chapman J. The early symptoms of schizophrenia. Br J Psychiatry. 112:1966;225-251.
15. Cleghorn J.M., Garnett E.S., Nahmias C., Firnau G., Brown G.M., Kaplan R., Szechtman H., Szechtman B. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res. 28:1989;119-133.
16. Creese I., Burt D.R., Snyder S.H. The dopamine receptor. differential binding of d-LSD and related agents to agonist and antagonist states Life Sciences. 17:1975;1715-1720.
17. de Belleroche J.S., Bradford H.F. Presynaptic control of the synthesis and release of dopamine from striatal synaptosomes. A coparison between the effects of 5-hydroxytryptamine, acetylcholine, and glutamate J Neurochem. 35:1980;1227-1234.
18. de Belleroche J.S., Gardiner I.M. Contrasting effects of 5-hydroxytryptamine on the release of dopamine and acetylcholine in the nucleus accumbens of rat. J Neural Transm. 55:1982;227-242.
19. De Deurwaerdere P., L'hirondel M., Bonhomme N., Lucas G., Cheramy A.X., Spampinato U. Serotonin stimulation of 5-HT4 receptors indirectly enhances in vivo dopamine release in the rat striatum. J Neurochem. 68:1997;195-203.
20. Dewey S.L., Smith G.S., Logan J., Brodie J.D., Fowler J.S., Wolf A.P. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse. 13:1993;350-356.
21. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.S., King P., Pappas N., Brodie J.D., Ashby C.R. Jr. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci. 15:1995;821-829.
22. Dittrich A. Psychological aspects of altered states of consciousness of the LSD type. measurements of their basic dimensions and prediction of individual differences Pletscher A., Ladewig D. 50 Years of LSD. Current Status and Perspectives of Hallucinogens. 1994;101-118 Parthenon Publishing, New York.
23. Dittrich A. Ätiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände. 1996;VWB-Verlag für Wissenschaft und Bildung, Stuttgart.
24. Ebmeier K.P., Blackwood D.H.R., Murray C., Souza V., Walker M., Doughall N., Moffoot A.P.R., O'Carroll R.E., Goodwin G.M. Single-photon emission computed tomography with 99mTc-Exametazime in unmedicated schizophrenic patients. Biol Psychiatry. 33:1993;487-495.
25. Ebmeier K.P., Lawrie S.M., Blackwood D.H., Johnstone E.C., Goodwin G.M. Hypofrontality revisited. a high resolution single photon emission computed tomography study in schizophrenia J Neurol Neurosurg Psychiat. 58:1995;452-456.
26. Ennis C., Kemp J.D., Cox B. Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the stritatum. J Neurochem. 36:1981;1515-1520.
27. Fahrenberg J., Hampel R., Selg H. Das Freiburger Persönlichkeitsinventar FPI. 1984;Hogrefe, Göttingen.
28. Fischman L.G. Dreams, hallucinogenic drug states, and schizophrenia. A psychological and biological comparison Schizophrenia Bull. 9:1983;73-94.
29. Freedman B., Chapman L.J. Early subjective experiences in schizophrenic episodes. J Abnorm Psychol. 82:1973;46-54.
30. Gouzoulis E., Hermle L., Sass H. Psychedelische Erlebnisse zu Beginn produktiver Episoden endogener Psychosen. Nervenarzt. 65:1994;198-201.
31. Gouzoulis-Mayfrank E., Hermle L., Thelen B., Sass H. History, rationale and potential of human experimental hallucinogen drug research in psychiatry. Pharmacopsychiat. 31:1998;63-68.
32. Guan X.M., McBride W.J. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull. 23:1989;541-547.
33. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine. Implications for serotonin-dopamine interactions J Neurochem. 66:1996;243-249.
34. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia. A postmortem study Biol Psychiatry. 42:1997;529-545.
35. Hasler F., Bourquin D., Brenneisen R., Bär T., Vollenweider F.X. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv. 72:1997;175-184.
36. Heimann H. Models of experience and behavior in psychotic disorders. Pharmacopsychiatry. 19:1986;128-133.
37. Hillegaart V., Estival A., Ahlenius S. Evidence for specific involvement of 5-HT1 and 5-HT2/AC receptors in the expression of patterns of spontaneous motor activity in the rat. Soc Neurosci Abstracts. 1:1995;1366.
38. Joyce J.N. The dopamine hypothesis of schizophrenia. limbic interactions with serotonin and norepinephrine Psychopharmacology. 112:1993;S16-S34.
39. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M., Kleinmann J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 8:1993;315-336.
40. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 153:1996;466-476.
41. Krebs-Thomson K., Geyer M.A. The role of 5-HT1A receptors in the locomotor-suppressant effects of LSD:way-100635 studies of 8-OH-DPAT, DOI and LSD. Behav Pharmacol. 6:1996;551-559.
42. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage. 4:1996;153-158.
43. Laruelle M., Abi-Dargham A., Casanova F., Toti R., Weinberger D.R., Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. Arch Gen Psychiatry. 50:1993;810-818.
44. Laruelle M., Abi-Dargham A., van Dyck C.H., Rosenblatt W., Zea-Ponce Y., Zoghbi S.S., Baldwin R.M., Charney D.S., Hoffer P.B., Kung H.F., Innis R.B. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 36:1995;1182-1190.
45. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A. 93:1996;9235-9240.
46. Liddle P.F., Friston K.J., Frith C.D., Hirsch S.R., Jones T., Frackowiak R.S. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry. 160:1992;179-186.
47. Marek G.J., Aghajanian G.K. Excitation of interneurons in piriform cortex by 5-hydroxytryptamine. blockade by MDL 100,907, a highly selective 5-HT2A receptor antagonist Eur J Pharmacol. 259:1994;137-141.
48. McCabe M.S., Fowler R.C., Cadoret R.J., Winokur G. Symptom differences in schizophrenia with good and poor progosis. Am J Psychiatry. 128:1972;1239-1243.
49. McKenna D.J., Nazarali A.J., Hoffman A.J., Nichols D.E., Mathis C.A., Saavedra J.M. Common receptors for hallucinogens in rat brain. a comparative autoradiographic study using (125 I) LSD and (125 I) DOI, a new psychotomimetic radioligand Brain Res. 476:1989;45-56.
50. McKenna D.J., Repke D.B., Peroutka S.J. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology. 29:1990;193-198.
51. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophrenia Bull. 17:1991;263-287.
52. Mita T., Hananda S., Nishino N., Kuno T., Nakai H., Yamdori T., Mizoi Y., Tanaka C. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry. 21:1986;1407-1414.
53. Neal-Beeliveau B., Joyce I., Lucki I. Serotonergic involvement in haloperidol induced catalepsy. J Pharmacol Exp Ther. 265:1993;207-217.
54. Nomikos G.G., Arborelius L., Hook B.B., Hachsell U., Svensson T.H. The 5-HT1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nuccleus accumbens and striatum. J Neural Transm. 103:1996;541-554.
55. Nordström A.-L., Farde L., Pauli S., Litton J.-E., Halldin C. PET analysis of central (11C) raclopride binding in healthy young adults and schizophrenic patients-reliability and age effects. Human Psychopharmacology. 7:1992;157-165.
56. Padich R.A., McCloskey T.C., Kehne J.H. (1996): 5-HT modulation of auditory and visual sensorimotor gating:II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology 124:107-116.
57. Palacios J.M., Wäber C., Mengold G., Pompeiano M. Molecular neuroanatomy of 5-HT receptors. Fozard J., Saxena P. Serotonin. Molecular Biology, Receptors and Functional Effects:1991;5-19 Birkhäuser Verlag, Basel.
58. Palfreyman M.G., Schmidt C.J., Sorensen S.M., Dudley M.W., Kehne J.H., Moser P., Gittos M.W., Carr A.A. Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology. 112:1993;S60-S77.
59. Parellada E., Catafau A.M., Bernardo M., Lomeña F., González-Monclús E., Setoain J. Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients. a resting and activation SPECT study Psychiatry Research: Neuroimaging. 55:1994;131-139.
60. Parson L.H., Justice J.B. Perfusate serotonin increases extracellular dopamine release in the nucleus accumbens as mesuered by in vivo microdialysis. Brain Res. 602:1993;195-199.
61. Pierce P.A., Peroutka S.J. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology. 97:1989;118-122.
62. Rümmele W., Gnirss F. Untersuchungen mit Psilocybin, einer psychotropen Substanz aus Psilocybe Mexicana. Schweiz Arch Neurol Psychiat. 87:1961;365-385.
63. Sabri O., Erkwoh R., Schreckenberger M., Owega A., Sass H., Buell U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet. 349:1997;1735-1739.
64. Schmidt C.J., Fadayel G.M., Sullivan C.K., Taylor V.L. 5-HT2 receptors exert a state-dependent regulation of dopaminergic function. studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine Eur J Pharmacol. 223:1992;65-74.
65. Schmidt C.J., Kehne J.H., Carr A.A., Fadayel G.M., Humphreys T.M., Kettler H.J., McCloskey T.C., Padich R.A., Taylor V.L., Sorensen S.M. Contribution of serotonin neurotoxins to understanding psychiatric disorders. The role of 5-HT2 receptors in schizophrenia and antipsychotic activity Int Clin Psychopharmacol. 8(Suppl 2):1993;25-32.
66. Schmidt C.J., Sullivan C.K., Fadayel G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem. 62:1994;1382-1389.
67. Siegel B.V.J., Buchsbaum M.S., Bunney W.E.J., Gottschalk L.A., Haier R.J., Lohr J.B., Lottenberg S., Najafi A., Nuechterlein K.H., Potkin S.G., Wu J.C. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry. 150:1993;1325-1336.
68. Sipes T.A., Geyer M.A. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology. 33:1994;441-448.
69. Sipes T.A., Geyer M.A. 8-OH-DPAT disruption of prepulse inhibition in rats. reversal with (+)WAY 100,135 and localization of site of action Psychopharmacology. 117:1995;41-48.
70. Smith G.S., Dewey S.L., Brodie J.D., Logan J., Vitkun S.A., Simkowitz P., Schloesser R., Alexoff D.A., Hurley A., Cooper T., Volkow N.D. Serotonergic modulation of dopamine measured with [11C] raclopride and PET in normal human subjects. Am J Psychiatry. 154:1997;490-496.
71. Spitzer M., Thimm M., Hermle L., Holzmann P., Kovar A., Heimann H., Gouzoulis E., Kischka U., Schneider F. Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry. 39:1996;1055-1057.
72. Tiihonen J., Kuoppamaki M., Nagren K., Bergman J., Eronen E., Syvalahti E.X., Hietala J. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology. 126:1996;277-280.
73. Volkow N.D., Fowler J.S., Wang G.J., Dewey S.L., Schlyer D., MacGregor R.L., Logan J., Alexoff D., Shea C., Hitzemann R., Angrist B., Wolf Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med. 34:1993;609-613.
74. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F.I., Bäbler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 9:1998;3897-3902.
75. Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 16:1997;357-372.
76. West A.R., Galloway M.P. Regulation of serotonin-facilitated dopamine release in vivo. the role of protein kinase A activating transduction mechanisms Synapse. 23:1996;20-27.
77. Westfall T.C., Tittermary V. Inhibition of the electrically induced release of [3H] dopamine by serotonin from superfused rat striatal slices. Neurosci Lett. 28:1982;205-209.
78. Yamamoto B.K., Nash J.F., Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther. 273:1995;1063-1070.
79. Zazpe A., Artaiz I., Del Rio J. Role of 5-HT3 receptors in basal and K(+)-evoked dopamine release from rat olfactory tubercle and striatal slices. Br J Pharmacol. 113:1994;968-972.